1/
🔥EXCELLENT results for Phase III multicentric double-blind RCT of #proxalutamide for hospitalized #COVID_19 patients🔥
n=588
Study led by @FlavioCadegiani in 🇧🇷
92% reduction in mortality ! prnewswire.com/news-releases/…
🔥EXCELLENT results for Phase III multicentric double-blind RCT of #proxalutamide for hospitalized #COVID_19 patients🔥
n=588
Study led by @FlavioCadegiani in 🇧🇷
92% reduction in mortality ! prnewswire.com/news-releases/…
2/
Keep in mind that this is a press release, not a scientific publication.
A point is particularly unclear in the press release, i.e. authors claim 588 patients were enrolled, but then later write they were 294 in proxalutamide group & 296 in control group.
294+296=590≠588.
Keep in mind that this is a press release, not a scientific publication.
A point is particularly unclear in the press release, i.e. authors claim 588 patients were enrolled, but then later write they were 294 in proxalutamide group & 296 in control group.
294+296=590≠588.
3/
Detailed results were shared in Portuguese during this press conference in 🇧🇷
Detailed results were shared in Portuguese during this press conference in 🇧🇷
https://twitter.com/Covid19Crusher/status/1369783896150315010
4/
These Phase III data are the best results seen hitherto among hospitalized COVID-19 patients. They confirm the excellent Phase II results published earlier by the same group of investigators
These Phase III data are the best results seen hitherto among hospitalized COVID-19 patients. They confirm the excellent Phase II results published earlier by the same group of investigators
https://twitter.com/julienpotet/status/1364130021401628675
5/
#Proxalutamide is a novel #androgen-receptor antagonist, initially developed for prostate cancer.
Androgen-receptor antagonists are postulated to downregulate #TMPRSS2. They include registered drugs like bicalutamide.
#Proxalutamide is a novel #androgen-receptor antagonist, initially developed for prostate cancer.
Androgen-receptor antagonists are postulated to downregulate #TMPRSS2. They include registered drugs like bicalutamide.
https://twitter.com/julienpotet/status/1264994473983070208
6/
Other classes of drugs targeting TMPRSS2 should be further investigated for treatment of COVID-19. This strategy has been way too neglected...😧
My personal preference goes for #bromhexine, a cheap, safe per os mucolytic.
Other classes of drugs targeting TMPRSS2 should be further investigated for treatment of COVID-19. This strategy has been way too neglected...😧
My personal preference goes for #bromhexine, a cheap, safe per os mucolytic.
https://twitter.com/julienpotet/status/1368921995992326150
7/
If peer-review confirms these results, then #proxalutamide will become standard of care for #COVID_19 in hospitals. I'm curious to hear what Kintor, the small biotech in 🇨🇳 that owns patents for proxalutamide, plans to do to make it available worldwide. en.kintor.com.cn
If peer-review confirms these results, then #proxalutamide will become standard of care for #COVID_19 in hospitals. I'm curious to hear what Kintor, the small biotech in 🇨🇳 that owns patents for proxalutamide, plans to do to make it available worldwide. en.kintor.com.cn
8/
In sum:
▶️#Proxalutamide may well be the game-changer for hospitalized C19 patients. Awaiting peer review though.
▶️There are other (more acessible) anti-androgens, as well as other 💊 targeting TMPRSS2. RCTs urgently needed.
▶️Awaiting Kintor's access plan for proxalutamide.
In sum:
▶️#Proxalutamide may well be the game-changer for hospitalized C19 patients. Awaiting peer review though.
▶️There are other (more acessible) anti-androgens, as well as other 💊 targeting TMPRSS2. RCTs urgently needed.
▶️Awaiting Kintor's access plan for proxalutamide.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
